Trial Profile
Phase I/II, Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Jul 2016 New trial record